Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy
← catalyst calendarSponsored by Theravance Biopharma (industry) · TBPH — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
102estimated
Sites
79
Countries
Argentina, Australia, Austria +17
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-06-27 | actual | When the study began enrolling |
| Primary completion | Jan 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2023-01-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Symptomatic Neurogenic Orthostatic Hypotension
- MSA - Multiple System Atrophy
Interventions
- Drug: Ampreloxetine — also filed as TD-9855
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFChange in OHSA composite score at Week 8 during the double-blind RW period
measured 8-week randomized withdrawal period (Week 12 to Week 20)
Permalink · TBPH's whole pipeline · Catalyst calendar · Every registered study · What changed